Part I: Pfizer’s testimony leads the way as US pressure on India increases
Readers may remember our recent coverage of Pfizer’s Chief IP Counsel, Roy Waldron’s testimony before a hearing of the US House of Representatives and the heated exchange that followed between Waldron and the Indian Pharmaceutical Alliance (IPA) thereafter. Waldron’s main allegations were that the Indian Pharmaceutical patent regime flouted international trade rules and abused the compulsory license system and recommended that the US government use all means at its disposal to get India in line. IPA responded with a strong […]
Part I: Pfizer’s testimony leads the way as US pressure on India increases Read More »



